Achilles Therapeutics (ACHL) Competitors $1.48 0.00 (0.00%) As of 03/26/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ACHL vs. ZYBT, PVLA, ACB, ATXS, CMPX, HUMA, DRUG, MNPR, NVCT, and LFCRShould you be buying Achilles Therapeutics stock or one of its competitors? The main competitors of Achilles Therapeutics include Zhengye Biotechnology (ZYBT), Palvella Therapeutics (PVLA), Aurora Cannabis (ACB), Astria Therapeutics (ATXS), Compass Therapeutics (CMPX), Humacyte (HUMA), Bright Minds Biosciences (DRUG), Monopar Therapeutics (MNPR), Nuvectis Pharma (NVCT), and Lifecore Biomedical (LFCR). These companies are all part of the "pharmaceutical products" industry. Achilles Therapeutics vs. Zhengye Biotechnology Palvella Therapeutics Aurora Cannabis Astria Therapeutics Compass Therapeutics Humacyte Bright Minds Biosciences Monopar Therapeutics Nuvectis Pharma Lifecore Biomedical Achilles Therapeutics (NASDAQ:ACHL) and Zhengye Biotechnology (NASDAQ:ZYBT) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, community ranking, institutional ownership, media sentiment, analyst recommendations, dividends, earnings and profitability. Does the MarketBeat Community prefer ACHL or ZYBT? Achilles Therapeutics received 17 more outperform votes than Zhengye Biotechnology when rated by MarketBeat users. CompanyUnderperformOutperformAchilles TherapeuticsOutperform Votes1754.84% Underperform Votes1445.16% Zhengye BiotechnologyN/AN/A Do insiders and institutionals believe in ACHL or ZYBT? 56.4% of Achilles Therapeutics shares are owned by institutional investors. 5.4% of Achilles Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Does the media favor ACHL or ZYBT? In the previous week, Zhengye Biotechnology had 2 more articles in the media than Achilles Therapeutics. MarketBeat recorded 2 mentions for Zhengye Biotechnology and 0 mentions for Achilles Therapeutics. Achilles Therapeutics' average media sentiment score of 0.00 equaled Zhengye Biotechnology'saverage media sentiment score. Company Overall Sentiment Achilles Therapeutics Neutral Zhengye Biotechnology Neutral Is ACHL or ZYBT more profitable? Zhengye Biotechnology's return on equity of 0.00% beat Achilles Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Achilles TherapeuticsN/A -54.45% -47.68% Zhengye Biotechnology N/A N/A N/A Which has better earnings & valuation, ACHL or ZYBT? Zhengye Biotechnology has higher revenue and earnings than Achilles Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAchilles TherapeuticsN/AN/A-$69.67M-$1.65-0.90Zhengye Biotechnology$189.75M2.62N/AN/AN/A SummaryZhengye Biotechnology beats Achilles Therapeutics on 4 of the 7 factors compared between the two stocks. Get Achilles Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ACHL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ACHL vs. The Competition Export to ExcelMetricAchilles TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$60.83M$2.93B$5.42B$7.70BDividend YieldN/A1.91%5.44%4.33%P/E Ratio-0.9030.4322.1818.31Price / SalesN/A478.52397.31107.09Price / CashN/A168.6838.2034.62Price / Book0.423.786.834.25Net Income-$69.67M-$72.06M$3.20B$247.51M7 Day PerformanceN/A11.20%5.79%6.08%1 Month PerformanceN/A-7.31%-5.53%-3.77%1 Year Performance87.46%-19.90%16.85%4.60% Achilles Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ACHLAchilles TherapeuticsN/A$1.48flatN/AN/A$60.83MN/A-0.90250ZYBTZhengye BiotechnologyN/A$5.12+26.1%N/AN/A$241.49M$189.75M0.00278High Trading VolumePVLAPalvella Therapeutics3.4704 of 5 stars$24.44+12.3%$44.43+81.8%N/A$239.77M$42.81M-2.02N/AACBAurora Cannabis0.2717 of 5 stars$4.25-0.7%N/A-40.7%$238.91M$320.81M85.021,340ATXSAstria Therapeutics2.4534 of 5 stars$4.22+4.5%$26.60+530.3%-46.2%$238.15MN/A-2.0230News CoveragePositive NewsCMPXCompass Therapeutics3.401 of 5 stars$1.72+1.5%$13.38+677.6%+36.2%$237.85M$850,000.00-4.6520Analyst ForecastNews CoverageHUMAHumacyte2.2742 of 5 stars$1.49-2.6%$13.71+820.4%-62.6%$237.33M$1.57M-1.11150DRUGBright Minds Biosciences3.3413 of 5 stars$32.75+13.6%$84.33+157.5%+2,944.6%$230.69MN/A-192.64N/ANews CoveragePositive NewsGap UpMNPRMonopar Therapeutics1.0683 of 5 stars$37.49+7.5%$55.33+47.6%+1,176.0%$229.18MN/A-19.0310NVCTNuvectis Pharma2.0218 of 5 stars$9.78+17.7%$15.67+60.2%+58.0%$228.77MN/A-8.438Positive NewsGap UpLFCRLifecore Biomedical1.8307 of 5 stars$6.17+6.0%$8.00+29.7%-1.7%$228.44M$130.86M-11.02690 Related Companies and Tools Related Companies ZYBT Alternatives PVLA Alternatives ACB Alternatives ATXS Alternatives CMPX Alternatives HUMA Alternatives DRUG Alternatives MNPR Alternatives NVCT Alternatives LFCR Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ACHL) was last updated on 4/24/2025 by MarketBeat.com Staff From Our PartnersJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredTrump’s treachery Forget what the media tells you. Trump’s inner circle may be pushing a financial reset that mirrors moves from...Porter & Company | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredThe Collapse Is Already HereWhen a system is about to fail, those trained to spot it often notice before anyone else. Tim Plaehn flew high...Investors Alley | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | SponsoredDo this Before Elon's Reveal on April 23rdElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | Sponsored‘Wheels Are Falling Off’ the U.S. Stock MarketThe last time the U.S. economy looked like this, stocks didn't move for 16 years... And many investors lost...Stansberry Research | Sponsored🥾⛏️👷♂️ What I Learned From Numerous Mine Visits...Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Achilles Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Achilles Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ACHL Stock Free ACHL Stock Alerts